Division of Daiichi Sankyo Co. Ltd.
Latest From Plexxikon Inc.
Further progress for Daiichi Sankyo's strategic push into oncology as US issues first approval globally for first-in-class rare disease drug Turalio - but with liver toxicity safeguards.
Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?
Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.
As part of its strategic pivot towards oncology, Daiichi Sankyo reaches a global out-licensing deal with a little-known US venture for an early-stage asset, which also hints at where its priorities lie.
Drug Discovery Tools
- Drug Discovery Tools
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Daiichi Sankyo Co. Ltd.
- Senior Management
K. Peter Hirth, PhD, CEO
Kathleen Sereda Glaub, Pres.
Gideon E Bollag, PhD, SVP, Research
- Contact Info
Phone: (510) 647-4000
91 Bolivar Dr.
Berkeley, CA 94710
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.